Oncology Business Management

End-of-life palliative care consultations can significantly reduce healthcare utilization, according to a broad-based population study published in the Journal of Oncology Practice.

It is not far-fetched to believe that, one day soon, automated systems will be able to obtain payer approval for therapies without any human involvement.

Despite all the excitement and anticipation, there is a growing anxiety among payers and providers regarding the cost of CAR T cells.

Investigators at Cota, a New York medical data analytics company, are taking further strides toward putting their growing knowledge of variance in care to work in the clinical setting.

The FDA has approved inotuzumab ozogamicin for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

The FDA has granted a priority review to a supplemental biologics license application for brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma.

This commentary from Maurie Markman, MD, highlights a critical required component for the development of effective novel antineoplastic strategies through the process widely known as precision cancer medicine.

Despite improved outcomes with new treatment and targeted therapies, patients with cancer continue to be afflicted by distressing symptoms and serious toxicities, which affect daily functioning and quality of life.

Architects can tailor new buildings to oncology’s specific needs and Arizona Oncology built its newest facility from the ground up rather than renting generic offices.

When it comes to treating older populations for cancer, it’s often the case that the only available data are based on trials of younger patients in far healthier condition.

The Medicare Payment Advisory Commission (MedPAC) voted to approve several proposals aimed at decreasing Medicare spending for Part B physician-administered drugs.

To optimize clinical outcomes and reduce the total cost of care, it is important to limit physicians’ choices of care.

The FDA has granted a priority review to a supplemental new drug application for alectinib (Alecensa) for the frontline treatment of patients with ALK-positive locally advanced or metastatic non–small cell lung cancer.

The FDA has approved CPX-351 for adult patients with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.

The FDA granted a priority review in March to a new drug application for maintenance olaparib, and is scheduled to make its final decision on the PARP inhibitor before the end of the year.

Frontline durvalumab (Imfinzi) did not improve progression-free survival in patients with stage IV metastatic non–small cell lung cancer compared with standard platinum-based chemotherapy.